CervoMed Correlations
| CRVO Stock | 7.41 0.44 6.31% |
The current 90-days correlation between CervoMed and Gain Therapeutics is 0.25 (i.e., Modest diversification). A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CervoMed moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CervoMed moves in either direction, the perfectly negatively correlated security will move in the opposite direction.
CervoMed Correlation With Market
Average diversification
The correlation between CervoMed and DJI is 0.13 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding CervoMed and DJI in the same portfolio, assuming nothing else is changed.
Moving together with CervoMed Stock
| 0.81 | OPTI | OptiBiotix Health Plc | PairCorr |
| 0.61 | 688238 | OBiO Technology Corp | PairCorr |
| 0.89 | 688089 | Cabio Biotech Wuhan | PairCorr |
| 0.71 | 300439 | Ningbo MedicalSystem | PairCorr |
| 0.78 | 300942 | Shenzhen Bioeasy Bio | PairCorr |
| 0.81 | METROPOLIS | Metropolis Healthcare | PairCorr |
| 0.61 | 300871 | Wuhan Hvsen Biotechnology | PairCorr |
| 0.73 | OBI | Ondine Biomedical | PairCorr |
| 0.81 | 688166 | BrightGene Bio Medical | PairCorr |
Moving against CervoMed Stock
| 0.87 | ZYME | Zymeworks Common Stock | PairCorr |
| 0.78 | IMNM | Immunome Earnings Call This Week | PairCorr |
| 0.76 | ZBIO | Zenas BioPharma, Common | PairCorr |
| 0.63 | UPB | Upstream Bio, | PairCorr |
| 0.6 | DYAI | Dyadic International | PairCorr |
| 0.4 | 603122 | Cowealth Medical China | PairCorr |
| 0.39 | VYNE | Vyne Therapeutics | PairCorr |
| 0.78 | ANAB | AnaptysBio | PairCorr |
| 0.71 | 600201 | Jinyu Bio Technology | PairCorr |
| 0.6 | REGN | Regeneron Pharmaceuticals | PairCorr |
| 0.56 | QNRX | Quoin Pharmaceuticals | PairCorr |
| 0.48 | CIZ | Cizzle Biotechnology | PairCorr |
| 0.47 | ABCL | Abcellera Biologics | PairCorr |
| 0.44 | MURA | Mural Oncology plc | PairCorr |
| 0.38 | NTLA | Intellia Therapeutics | PairCorr |
| 0.34 | PYPD | PolyPid | PairCorr |
Related Correlations Analysis
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between CervoMed Stock performing well and CervoMed Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze CervoMed's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| GANX | 4.65 | 0.79 | 0.22 | 0.35 | 4.05 | 11.36 | 25.41 | |||
| ADAG | 4.25 | 0.03 | (0.01) | 0.20 | 5.47 | 10.14 | 37.74 | |||
| XBIT | 2.64 | (0.25) | 0.00 | (0.02) | 0.00 | 5.82 | 16.38 | |||
| OSTX | 3.22 | 0.02 | 0.02 | 0.13 | 4.08 | 6.39 | 26.06 | |||
| NTRB | 3.24 | (0.37) | 0.00 | (0.07) | 0.00 | 8.42 | 26.20 | |||
| ACET | 4.16 | 0.12 | 0.03 | 0.22 | 5.06 | 9.41 | 35.48 | |||
| NRXP | 3.75 | 0.05 | 0.03 | 0.15 | 4.10 | 9.55 | 23.02 | |||
| FBIO | 4.35 | 0.73 | 0.08 | (0.93) | 6.27 | 9.38 | 61.44 | |||
| LITS | 4.95 | (1.31) | 0.00 | (0.57) | 0.00 | 7.73 | 36.65 | |||
| VTVT | 2.70 | 1.12 | 0.37 | 1.56 | 2.01 | 7.57 | 20.53 |
CervoMed Corporate Management
| Dr Cobuzzi | Chief Officer | Profile | |
| Mark Rosch | Government Regulatory | Profile | |
| Claudia MD | Senior Science | Profile | |
| John Tanner | Chief Officer | Profile | |
| Matthew Winton | Chief Officer | Profile | |
| Marinus Verwijs | Executive Operations | Profile |